Canaccord Adams Maintains a 'Buy' on ImmunoGen (IMGN); T-DM1 Reg Strategy Expected
Tweet Send to a Friend
Canaccord Adams maintains a 'Buy' rating on ImmunoGen (Nasdaq: IMGN), price target $9.50.
Canaccord analyst says, "...Bullish management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "...Bullish management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
